You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》康宁杰瑞制药(09966.HK)料PD-L1产品明年上半年可申请在内地上市
阿思达克 12-12 10:42

康宁杰瑞制药(09966.HK)首席执行官徐霆出席上市仪式後表示,公司的PD-L1产品希望明年上半年可申请在内地上市,如顺利,明年或2021年可获上市许可。针对内地药物「带量采购」的政策,他认为由於公司主要做创新药,加上定位全球市场,故关系并不大,但创新药能否被纳入医保则有影响,之前国内亦有PD-L1药物进入医保,而其价格仍有利润空间,因此并不担心。

在海外拓展方面,他指公司双抗产品在全球竞争力处於前列,现时在很多肿瘤实验亦有良好的初步成果,故认为公司具前景。被问及何时扭亏,首席财务官帅琪指出药品将来的盈利难在现阶段作预测,而中国政策有不断改变的地方,公司近一、两年仍会保持投入,故仍会录亏损。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account